Krithika Rajagopalan

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder
    Krithika Rajagopalan
    Health Economics Outcomes Research, AstraZeneca Pharmaceuticals, Wilmington, DE 19850 5437, USA
    Curr Med Res Opin 22:443-52. 2006
  2. ncbi Employee costs before and after treatment initiation for bipolar disorder
    Richard A Brook
    Retrospective Analysis, The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
    Am J Manag Care 13:179-86. 2007
  3. ncbi Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye
    Krithika Rajagopalan
    AstraZeneca Pharmaceuticals, Wilmington, DE 76134 2099, USA
    Value Health 8:168-74. 2005
  4. pmc Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
    Judith J Stephenson
    HealthCore Inc, Wilmington, DE 19801, USA
    Health Qual Life Outcomes 10:155. 2012
  5. ncbi Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey
    Siddhesh A Kamat
    1 HealthCore Inc, Wilmington, Delaware, USA 2 Biogen Idec, Cambridge, Massachusetts, USA
    Patient 2:105-12. 2009
  6. ncbi Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population
    Siddhesh A Kamat
    HealthCore, Wilmington, Delaware 19801, USA
    J Manag Care Pharm 14:631-42. 2008
  7. ncbi A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life
    Jean Endicott
    New York State Psychiatric Institute, New York City, NY 10032, USA
    Int Clin Psychopharmacol 22:29-37. 2007
  8. ncbi Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder
    Frank D Gianfrancesco
    HECON Associates, Inc, Montgomery Village, Maryland 20886, USA
    Clin Ther 30:1358-74. 2008
  9. ncbi Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Curr Med Res Opin 22:2233-42. 2006
  10. ncbi The effect of medication adherence on health care utilization in bipolar disorder
    Kim H Lew
    Health Informatics and Outcomes Research, Prescription Solutions, Irvine, California 92614 6223, USA
    Manag Care Interface 19:41-6. 2006

Collaborators

Detail Information

Publications16

  1. ncbi Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder
    Krithika Rajagopalan
    Health Economics Outcomes Research, AstraZeneca Pharmaceuticals, Wilmington, DE 19850 5437, USA
    Curr Med Res Opin 22:443-52. 2006
    ..To compare the cost and utilization of health care services for various comorbid conditions among employees with bipolar disorder (BPD) and two other population cohorts: employees without BPD and employees with other mental disorders (OMD)...
  2. ncbi Employee costs before and after treatment initiation for bipolar disorder
    Richard A Brook
    Retrospective Analysis, The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
    Am J Manag Care 13:179-86. 2007
    ..To examine pretreatment and posttreatment total medical costs and overall mental healthcare costs for patients with bipolar disorder (BPD) treated with different medication regimens (alone and in combination) vs an untreated (UnTx) cohort...
  3. ncbi Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye
    Krithika Rajagopalan
    AstraZeneca Pharmaceuticals, Wilmington, DE 76134 2099, USA
    Value Health 8:168-74. 2005
    ....
  4. pmc Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
    Judith J Stephenson
    HealthCore Inc, Wilmington, DE 19801, USA
    Health Qual Life Outcomes 10:155. 2012
    ..We investigated the impact of natalizumab on patient-reported outcomes (PROs) in a real-world setting...
  5. ncbi Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey
    Siddhesh A Kamat
    1 HealthCore Inc, Wilmington, Delaware, USA 2 Biogen Idec, Cambridge, Massachusetts, USA
    Patient 2:105-12. 2009
    ..To assess multiple sclerosis (MS) patients' experience with natalizumab (TYSABRI, Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.) in a clinical practice setting...
  6. ncbi Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population
    Siddhesh A Kamat
    HealthCore, Wilmington, Delaware 19801, USA
    J Manag Care Pharm 14:631-42. 2008
    ..Because the depressive episodes in bipolar disorder may be indistinguishable from those in major depressive disorder (MDD), misdiagnosis may occur...
  7. ncbi A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life
    Jean Endicott
    New York State Psychiatric Institute, New York City, NY 10032, USA
    Int Clin Psychopharmacol 22:29-37. 2007
    ..Improved quality of life may enhance patient compliance, and assessment of quality of life should be incorporated into future clinical trials in bipolar depression...
  8. ncbi Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder
    Frank D Gianfrancesco
    HECON Associates, Inc, Montgomery Village, Maryland 20886, USA
    Clin Ther 30:1358-74. 2008
    ..Up to 48% of patients with bipolar disorder are either nonadherent or partially adherent to antipsychotic drug treatment. Medication adherence may differ by bipolar disorder subtype...
  9. ncbi Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Curr Med Res Opin 22:2233-42. 2006
    ..To present a tool that allows estimation of the budget impact of treatments for acute mania in bipolar I disorder from a US healthcare payer perspective...
  10. ncbi The effect of medication adherence on health care utilization in bipolar disorder
    Kim H Lew
    Health Informatics and Outcomes Research, Prescription Solutions, Irvine, California 92614 6223, USA
    Manag Care Interface 19:41-6. 2006
    ..98; 95% confidence interval, 1.38-2.84) and inpatient hospitalizations (odds ratio, 1.71; 95% confidence interval, 1.27-2.32), even after adjusting for age, gender, and comorbidity...
  11. ncbi The economic impact of bipolar disorder in an employed population from an employer perspective
    Harold H Gardner
    Human Capital Management Services, Cheyenne, WY 82001, USA
    J Clin Psychiatry 67:1209-18. 2006
    ..To determine the economic impact of bipolar disorder on health benefit costs and health-related work absences from an employer perspective...
  12. ncbi Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics
    Frank D Gianfrancesco
    HECON Associates, Inc, Montgomery Village, MD 20886, USA
    J Clin Psychiatry 67:222-32. 2006
    ..This retrospective claims-based study evaluated treatment adherence among patients with bipolar or manic disorder treated with atypical and typical antipsychotics...
  13. ncbi Quality-of-life improvements in cataract patients with bilateral blue light-filtering intraocular lenses: clinical trial
    Derek Espindle
    Mapi Values, Boston, Massachusetts, USA
    J Cataract Refract Surg 31:1952-9. 2005
    ....
  14. ncbi Lost time, absence costs, and reduced productivity output for employees with bipolar disorder
    Nathan L Kleinman
    HCMS Group, Cheyenne, Wyoming 82001, USA
    J Occup Environ Med 47:1117-24. 2005
    ..We sought to evaluate the incremental health-related lost work time and at-work productivity loss for employees with bipolar disorder (BPD)...
  15. ncbi The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample
    Polyxane Mertzanis
    Mapi Values, Boston, Massachusetts 02108, USA
    Invest Ophthalmol Vis Sci 46:46-50. 2005
    ..To assess the relative burden of dry eye in daily life by comparing Short Form-36 (SF-36) responses from individuals with and without dry eye against U.S. norms...
  16. ncbi The economic burden of dry eye: a conceptual framework and preliminary assessment
    Prabashni Reddy
    Abt Associates Inc, 55 Wheeler Street, Cambridge, Massachusetts 02138, USA
    Cornea 23:751-61. 2004
    ..To develop a conceptual framework for analyzing the economic burden of dry eye and a preliminary assessment of key factors that contribute to that burden...